SLGL Sol-Gel Technologies Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1684693 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY68.0%
TTM net income YoY42.1%
TTM EPS YoY42.2%
Revenue 3-yr CAGR70.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-38.9%
Net margin-31.6%
FCF margin1.4%
EBITDA margin-38.3%
Returns
ROE-23.7%
ROA-18.6%
ROIC (approx.)-56.3%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio4.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.05x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $19.39M | $11.54M | $1.55M | $3.88M | $31.27M |
| R&D expense | $22.80M | $17.80M | $23.54M | $12.68M | $20.38M |
| SG&A expense | $4.18M | $5.75M | $7.37M | $7.45M | $8.45M |
| Operating income | -$7.54M | -$12.01M | -$29.30M | -$16.24M | $2.96M |
| Pretax income | — | — | — | — | $3.22M |
| Income tax | $0 | $0 | $0 | — | $0 |
| Net income | -$6.13M | -$10.58M | -$27.24M | -$14.92M | $3.22M |
| EBITDA | -$7.43M | -$11.78M | -$28.96M | -$15.68M | $3.84M |
| EPS (basic) | -2.19 | -3.79 | -10.01 | -0.65 | 0.14 |
| EPS (diluted) | -2.19 | -3.79 | -10.01 | -0.65 | 0.14 |
| Weighted avg. shares (diluted) | 2.79M | 2.79M | 2.71M | 23.13M | 23.57M |
| Balance sheet | |||||
| Cash & equivalents | $11.03M | $19.49M | $7.51M | $13.60M | $21.23M |
| Short-term investments | $12.97M | $4.42M | $20.47M | $8.68M | $1.71M |
| Receivables | $1.97M | $3.60M | $377,000 | $62,000 | $13.06M |
| Current assets | $26.97M | $31.30M | $41.17M | $43.05M | $57.11M |
| PP&E, net | $140,000 | $202,000 | $434,000 | $660,000 | $1.05M |
| Total assets | $29.92M | $35.85M | $45.29M | $46.63M | $69.19M |
| Current liabilities | $6.17M | $5.29M | $4.52M | $3.33M | $11.69M |
| Total liabilities | $7.11M | $7.00M | $6.64M | $4.42M | $13.60M |
| Shareholders' equity | $22.81M | $28.85M | $38.64M | $42.21M | $55.59M |
| Shares outstanding | 2.79M | 2.79M | 27.86M | 23.13M | 23.13M |
| Cash flow statement | |||||
| Operating cash flow | $322,000 | -$13.89M | -$17.73M | -$9.48M | -$7.69M |
| Capital expenditure | $47,000 | $2,000 | $134,000 | $171,000 | $143,000 |
| Free cash flow | $275,000 | -$13.89M | -$17.86M | -$9.65M | -$7.83M |
| Investing cash flow | -$8.58M | $26.69M | -$9.74M | $1.70M | $19.87M |
| Financing cash flow | $6,000 | $0 | $21.81M | $15,000 | $837,000 |
| Depreciation & amortization | $109,000 | $233,000 | $342,000 | $562,000 | $880,000 |
| Stock-based compensation | $82,000 | $786,000 | $1.86M | $1.53M | $687,000 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.